DMSO and the Blood Vessels
Every part of your body that has ever repaired itself did it the same way, and the first thing it needed was blood flow.
It sounds too plain to hang a long article on. Oxygen and glucose come in, waste goes out, and the cells that do the repairing travel the same route. Cut that route and nothing downstream matters, including supplements, diet, and willpower. Tissue dies on a schedule, and the schedule runs in minutes. The compound that resets that schedule is older than most of the people reading this, costs less than a sandwich, and appears in thousands of papers that nobody teaches.
Which brings me to a side of DMSO that almost never makes it into the conversation. Everyone knows it as the solvent that carries other things through skin. Fewer people know that DMSO has been studied for fifty years as a vascular drug. It is an anticlotting agent and a vasodilator, it protects the endothelium, and it is one of the only compounds ever tested that can be given before a doctor knows what kind of stroke you are having.
Flow is the first medicine. Everything else is support.
The clot you cannot see
Most people picture a clot as a plug in a pipe, and they picture it happening in the heart or the brain, once, dramatically. Reality is duller and more common.
Blood gets sludgy. Red cells stack up in long rouleaux columns instead of sliding past each other. Platelets get prickly. Capillaries, which are narrower than a single red cell is wide, stop letting cells through one at a time and start letting a traffic jam form.
It is a drift rather than an event, and it runs for decades. A lot of what gets labeled vaguely as poor circulation, brain fog, cold hands, tired legs, or mystery fatigue sits downstream of it. It is also, I think, why so many people feel dramatically better on DMSO in ways their doctor cannot explain with one diagnosis.
The platelet channel
Platelets are the first responders. When they switch on, they throw out little arms called filopodia, grab each other, and release thromboxane A2, which recruits more platelets to the pile. Aspirin works by blocking one enzyme in that chain, cyclooxygenase-1.
DMSO blocks that same enzyme in platelets (one study measured a 36 percent cut in total COX activity at 0.5 percent), then acts on several other parts of the drift at once rather than jamming a single lever.
In the lab, DMSO suppressed human platelet clumping triggered by ADP, adrenaline, arachidonic acid, collagen, thrombin, and platelet-activating factor. ADP is usually the most sensitive. It also pulls down the surface markers that announce a platelet has gone active (P-selectin, PAC-1, GPIIb/IIIa, CD63, PF4), raises the two messengers that keep platelets quiet (cAMP and cGMP), and mops up the hydroxyl radicals that would otherwise trigger the whole cascade.
The part I find genuinely interesting is the physical one. DMSO changes the water structure at the platelet membrane, which makes the cell less responsive to being yanked on. Mechanical heart-assist devices shear platelets hard enough that ordinary antiplatelet drugs lose the fight.
85% — reduction in cyclic coronary flow drops in a dog model of critical stenosis, with no change in blood pressure or heart rate
2× — time to platelet aggregation in injured mouse brain arterioles (117 vs 57 seconds)
0 — thrombi formed in an injured rat carotid after IV DMSO, despite clear endothelial damage
DMSO held up under that shear, cutting adhesion under flow to about a fifth of control, and the platelets still responded normally to chemical signals afterward. The effect is closer to calming a platelet than switching it off.
In live animals that translates. A dog with a narrowed coronary artery, the kind where platelets pile up and flow drops in cycles, had those drops cut by up to 85 percent on IV DMSO. A rat with a deliberately injured carotid artery formed essentially no thrombus, and under electron microscopy the platelets at the injury site were round and inactive, sitting where a clot should have been.
The clotting cascade and the dissolving side
Platelets only start the process. The coagulation cascade is where a clot actually gets built, and DMSO acts there as well. It suppresses tissue factor, the protein that ignites the whole cascade and links inflammation to thrombosis, by way of JNK and p38 signaling. It alters thrombin's shape and behavior.
And it activates the cleanup crew: DMSO stimulates tissue plasminogen activator, the body's own clot dissolver, while reducing PAI-1, the brake on that process.
That combination, preventing new clots while helping the body break down existing ones, is why "fibrinolytic activity" shows up as a standard listed property of DMSO in the clinical literature rather than as an exotic claim from one paper.
Sludging starts in vessels too small to stent. DMSO works at that scale.
Opening the pipes
Vessels are not rigid tubes. They are wrapped in smooth muscle that tightens and relaxes on command, and DMSO relaxes it across nearly every vascular bed studied: aorta, coronary, pulmonary, mesenteric, renal, cerebral, umbilical, saphenous.
Part of that runs through the endothelium and nitric oxide. Part of it works directly on the muscle, blocking calcium entry, which matters because a damaged vessel with a wrecked lining can still be relaxed by something that does not need the lining to cooperate.
Some of the warmth people feel when they rub DMSO on is histamine-mediated dilation. That is a controlled effect, not an injury. When DMSO was injected into a limb, lymph flow rose sharply while the protein content of that lymph fell, which is the opposite of what a caustic agent does. Tissue examination showed dilated vessels and no cell death.
The radical scavenging matters here too, and in a way that is easy to miss. Hydroxyl radicals themselves dilate cerebral vessels. So DMSO both protects vessels from oxidative constriction and blocks dilation that free radicals were driving. So the direction of the effect depends on what the vessel was already doing. DMSO is removing a bad signal, and it pushes tone one way or the other only because of that.
The glycocalyx
Line the inside of every vessel and you find a fragile sugar gel called the glycocalyx. It regulates what crosses the wall, shields cells from shear, and keeps clotting and inflammation in check. In shock, sepsis, and reperfusion, it gets stripped off, and that shedding is now understood as one of the first events in vascular collapse.
In a mouse model of acute respiratory distress, systemic DMSO preserved pulmonary glycocalyx staining at roughly four times the level of untreated injury, cut protein leak into the airspaces, and reduced inflammatory cell counts. In human endothelial cells it blocked the enzyme that cleaves the glycocalyx off the cell surface. In hemorrhage models it reduced both shedding and the coagulopathy that follows.
Where the stroke math breaks
Stroke kills about 165,000 Americans a year and leaves a fifth to two-fifths of survivors with long-term disability. It is the second leading cause of death worldwide and the third leading cause of disability.
The bottleneck is triage, not talent.
Roughly 87 percent of strokes are ischemic, a clot blocking flow. About 13 percent are hemorrhagic, a bleed. The treatments are opposite, and giving the clot buster tPA to a bleed can kill the patient.
So nothing definitive happens until the patient is recognized, transported, scanned, read, and cleared. Even well-run systems lose hours to that sequence, and brain tissue does not wait.
Then there is tPA itself. Approved in 1996 and still the only FDA-approved drug for ischemic stroke. Only about a quarter of patients arrive inside the window, which works out to between 1.8 and 8.5 percent of ischemic stroke patients actually receiving it. Of those, about 13 percent significantly benefit.
The drug also carries a 6.4 percent risk of symptomatic brain bleed and a 1.6 percent risk of serious systemic hemorrhage. And there is essentially no therapy for recovery afterward, which is why the disability numbers have barely moved in thirty years.
DMSO does not require you to know which kind of stroke it is before you start. That single property is worth more than most of what is in the stroke protocol.
What de la Torre found
None of that is my claim. Jack de la Torre spent a career on it. In rhesus monkeys whose middle cerebral artery was blocked for four hours, then reopened after seventeen, DMSO produced significant protection from the neurological deficits and blood flow collapse that the untreated and dexamethasone groups developed.
In squirrel monkeys, 8 of 10 DMSO-treated animals were alive at seven days versus 34 percent with hemodilution and 75 percent with hyperbaric oxygen, and the DMSO group had milder deficits.
In a canine embolization model, DMSO-treated animals had no infarcted tissue where untreated animals had a measurable lesion.
The human trial
On the human side, a 2002 trial gave IV DMSO with fructose diphosphate to 11 acute and subacute ischemic stroke patients. Started within 12 hours, 63 percent improved or markedly improved at three months against 20 percent on standard care, and the benefit held even when treatment started well after the event.
The reperfusion piece is the one clinicians underestimate. When blood returns to oxygen-starved tissue, the returning oxygen becomes a burst of radicals, and that second injury often exceeds the first.
DMSO is among the best-known hydroxyl radical scavengers in biology, reliable enough that it is used as a laboratory probe for detecting hydroxyl radicals. It protects brain tissue, heart tissue, gut, lung, liver, and skin flaps from that burst.
Four hours of dead time versus a bottle in the glovebox.
Bleeds and brain pressure
Hemorrhagic stroke is where conventional medicine has the least to offer. Blood in the brain raises intracranial pressure inside a sealed skull, the blood-brain barrier breaks down, and the iron from dying red cells generates radicals that destroy the tissue around it. There is no good drug for intracranial pressure. Mannitol, the workhorse, can rebound, meaning pressure climbs higher than where it started.
Pressure down, perfusion up. Conventional tools trade one for the other.
Intracranial pressure
DMSO lowers intracranial pressure fast and does not rebound. In a study of 11 patients with dangerously high pressure and Glasgow scores of 4 to 6 after trauma, encephalitis, or subarachnoid hemorrhage, IV DMSO at 1 g/kg dropped pressure by roughly 23 mm Hg within 30 minutes and produced brisk diuresis, without sedation and without dropping systemic blood pressure, so perfusion pressure rose as pressure fell.
Three of the 11 survived with good function.
In ten patients with closed head trauma and pressures between 40 and 127 mm Hg against a normal of 5 to 13, pressure fell on average 28 mm Hg in 24 hours and 58 by day six, confirmed on CT. At three months, seven had minimal or no impairment.
Across a prospective series of 10 severe head injuries, pressure dropped a mean 23.5 mm Hg within ten minutes with no rebound, and seven survived.
That is the pattern that shows up over and over in this literature: an agent that lowers pressure while increasing flow, in a situation where every conventional tool trades one for the other.
The heart runs on the same logic
Cardiac muscle is as oxygen-sensitive as brain tissue. In a dog heart attack model, an IV bolus of DMSO raised cardiac output to 1.65 L/min by hour three against 1.15 in untreated controls, while lowering systemic vascular resistance and raising cerebral blood flow.
In isolated rat hearts, three days of pretreatment cut infarct size from 50 percent to 21.2 percent. In another model, DMSO reduced the damaged portion of the heart by 76 percent.
Where the heart data thins out
Not every cardiac study landed a clean result. The one that found nothing infused 50 percent DMSO straight into the artery, which is not the protocol anyone uses and is close to a different experiment. The rest cluster around real protection, with the size of the effect tracking how early and how sensibly it was given.
What the record supports is narrower and stronger than a promise: DMSO is worth having in the room when a heart or a brain loses its blood supply, and starting sooner beats starting later every time the data was checked. Nothing else in that room costs this little or carries this few risks.
Where people actually notice it
The peripheral stories are the ones that convince ordinary people, because they can see the before and after in a mirror.
Take varicose veins. In the early clinical series, Stanley Jacob reported half of Raynaud's patients had symptoms eliminated and thrombophlebitis responded excellently. Two investigators using plethysmography documented objective improvement in peripheral artery insufficiency across a large patient group.
A study of 67 patients with varicose ulcers found strong responses even in chronic ulcers that had failed everything else. Diabetic ulcer series report over 94 percent success rates. In one trial of venous ulcers, a DMSO powder healed 95 percent of patients at three months against 70 percent on placebo.
What readers report
Then the modern reader reports, and there are a lot of them.
Veins that had been visible for decades shrinking, softening, and in some cases disappearing over months of topical use. A clot in an arm vein from an IV reaction cleared in three days. A DVT from knee to ankle dissolved over two and a half months.
Toes that had gone blue-black from frostbite came back to healthy pink. An 85-year-old's feet coming back from a blackish-blue numb state to normal color and feeling in three weeks. Hemorrhoids that shrank after a single application.
Take the reader reports for what they are, and then notice the thing that matters: the trials and the testimonials describe the same effects, in the same order, at the same rough speed. In most of this field those two sources disagree. Here they don't, and that agreement is the part I trust.
Hands, feet, legs. The places poor flow announces itself first.
The one caution that actually matters
DMSO potentiates other things. That is its gift and its risk. If you are on a prescription anticoagulant, do not stack DMSO on top of it casually.
Space doses by at least two hours, keep monitoring your coagulation values, and never mix IV DMSO with an anticoagulant in the same infusion. The German DMSO community, which has the most combined experience here, considers concurrent use acceptable with monitoring and reports no meaningful shifts in INR, but that is a clinical judgment, not a green light for self-dosing.
Bleeding events reported with DMSO are rare and usually mild: a nosebleed, a cut that took two hours to stop in someone on Eliquis, one GI bleed in a person taking high oral DMSO alongside high-dose nattokinase. At the low doses reached by most topical and oral use, standard clotting parameters do not move much at all.
One thing here is not negotiable. If you think you are having a stroke, use DMSO on the way to the hospital. Do not use it instead of the hospital.
A major hemorrhagic stroke needs a neurosurgeon, and DMSO cannot substitute for that. The point is to arrive with less damage, not to avoid arriving.
The record is stronger than the institution admits
Add up what is actually on paper. Roughly fifteen hundred studies touch DMSO's effects on platelets, clotting, the endothelium, cerebral blood flow, and reperfusion injury. The Russian and Chinese literature alone runs to hundreds of clinical papers, many controlled, most never translated. Jack de la Torre published on DMSO and stroke for fifty years. Stanley Jacob treated stroke patients with it and wrote down what happened.
That is not a fringe literature. It is a mainstream literature that stopped being taught.
So when you hear that there is no evidence for DMSO in vascular disease, check what is being claimed. There is no FDA label. That is a different sentence, and the distance between the two is commercial, not scientific.
Which is also why the practical advice in this article is worth more than the label. You do not need permission to own a bottle. You need to know what it does, how fast it works, and where the real risks sit.
Why this stays in the shadows
DMSO is off patent. Nobody can spend a billion dollars on trials to own it, and in the current system, access to the medical marketplace is bought rather than earned.
The same molecule is used in tens of thousands of papers as a solvent for other drugs, and in a striking number of those studies the group that received only DMSO performed better than the placebo group should have. Authors usually do not mention it. Sometimes they cannot conceive of it.
There is also the practical stuff that killed early enthusiasm. Concentrated DMSO dissolves standard IV tubing. The volumes used in the 1980s were poorly suited to a head-injured patient. Nurses working in unventilated rooms with high-dose IV patients got headaches from dimethyl sulfide. Each of those was solvable, and each was used as a reason to stop.
Fifty years of evidence and thousands of studies do not add up to a business anyone can own, so it stays in the literature.
So you learn it yourself and use it carefully.
The stack that matches this logic
Our DMSO Healing Stack pairs 99.9% pure DMSO with the Sacred Salve, DMSO carrying frankincense into tissue that needs it. It follows the same logic as everything above. Get the compound into the tissue, and let circulation carry the rest.
Topical use. Not for injection. Read the label.
This article is educational and describes published research and reported experiences. It is not medical advice, diagnosis, or treatment, and it is not a substitute for emergency care. DMSO is not FDA-approved for the conditions discussed. If you take anticoagulants, have a bleeding disorder, or are pregnant, talk to your physician before use. Statements here have not been evaluated by the Food and Drug Administration.
© iHeal Collective · ihealcollective.com
Comments